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Differential expression of cyclin-dependent kinase inhibitors The mature podocyte (also known as the visceral glo-
in human glomerular disease: Role in podocyte proliferation merular epithelial cell) is a terminally differentiated cell
and maturation. that serves specialized functions in the glomerulus [1].
Background. Normal human podocytes are terminally dif-
During glomerulogenesis, immature or undifferentiatedferentiated and quiescent cells. It is not known why podocytes
podocytes engage the cell cycle and proliferate [2]. How-fail to proliferate in response to most forms of injury. Prolifera-
ever, upon acquiring a mature and differentiated pheno-tion is regulated by cell cycle proteins and their inhibitors. The
Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors type, podocytes exit the cell cycle and cease proliferating
(p21, p27, p57) in general prevent proliferation by inhibiting so that mature podocytes exhibit a quiescent phenotype
cyclin-CDK complexes. In the current study, we determined [3, 4]. The podocyte response to injury in glomerular
the expression and possible role of specific CDK inhibitors
disease includes flattening and effacement of foot pro-in podocyte proliferation in human disease characterized by
cesses, and in more severe injury, this is associated withpodocyte injury.
podocyte detachment from the underlying glomerularMethods. Immunostaining was performed for the CDK in-
hibitors p21, p27, and p57 and the proliferation marker Ki-67 basement membrane [1]. Recently, potential prolifera-
on renal biopsies from patients with minimal change disease tive responses of mature podocytes to injury have been
(MCD; N 5 6), membranous glomerulopathy (MGN; N 5 19), recognized and are a subject of considerable debate [5].
cellular variant of focal segmental glomerulosclerosis (FSGS; In glomerular diseases in which the podocyte is a pri-N 5 12), collapsing glomerulopathy (CG; N 5 9), and HIV-
mary target of injury, such as minimal change diseaseassociated nephropathy (HIVAN; N 5 16). Adult nephrectomy
(MCD) and membranous nephropathy [6], it is generallyspecimens without evidence of glomerular disease served as
controls (N 5 9). accepted that podocytes do not re-engage the cell cycle
Results. Normal quiescent podocytes express p27 and p57, and maintain their terminally differentiated phenotype.
but not p21. In diseases without podocyte proliferation (MCD, In some forms of focal segmental glomerulosclerosis
MGN), p21, p27, and p57 expression did not change. In con- (FSGS), podocytes detach from the underlying glomeru-trast, there was a uniform decrease in p27 and p57 immuno-
lar basement membrane following injury. Studies havestaining in diseases with podocyte proliferation (cellular FSGS,
shown that the inability of podocytes to proliferate andCG, and HIVAN). This was accompanied by the de novo
expression of p21 in podocytes. replace those lost in this injury process may result in a
Conclusions. Our results show that podocyte quiescence may denuded glomerular basement membrane, which leads
require the presence of the CDK inhibitors p27 and p57. In to the development of glomerulosclerosis [7–9].
human glomerular diseases, a decrease in p27 and p57 may be More recently, it has been recognized that podocytes
permissive for the altered proliferative podocyte phenotype. p21
proliferate in response to certain forms of injury. The cel-may have a multifactorial role in podocyte cell cycle regulation.
lular variant of FSGS [10], collapsing glomerulopathy (CG)
[11–13], and HIV-associated nephropathy (HIVAN) [11]
are characterized by glomerular cell proliferation. TheKey words: cell cycle, kidney, proliferation, glomerular podocytes, vis-
ceral glomerular epithelial cell. origin of the proliferating cells in CG has been somewhat
controversial. Barisoni et al [11] and Bariety et al [14]Received for publication October 4, 1999
showed a predominance of podocyte proliferation in id-and in revised form February 11, 2000
Accepted for publication March 4, 2000 iopathic CG. In contrast, Nagata et al showed that pari-
etal epithelial cells proliferate in CG [15]. It has evenÓ 2000 by the International Society of Nephrology
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been suggested that these cells may be monocytes arising The subgroups of cellular FSGS and CG were defined
according to previously described morphologic and clini-from transformed podocytes [14].
Cell proliferation and, to some extent, cell differentia- cal features [11]. All patients with CG had negative HIV
serologies. In all patients with HIVAN, diagnosis wastion are controlled at the level of the cell cycle by cell
cycle-regulatory proteins. Proliferation requires that spe- confirmed by demonstration of serum antibodies to HIV-1
using enzyme-linked immunosorbent assay (ELISA)cific cyclin-dependent kinases (CDKs) are activated by
a partner cyclin in each phase of the cell cycle [16]. Thus, followed by Western blot. For control tissues without
glomerulopathy, macroscopically normal-appearing re-CDK4 and CDK6 are activated by D-type cyclins in early
G1 phase of the cell cycle. CDK2 is activated by cyclin nal tissues were obtained from nephrectomies (N 5 9)
performed for localized renal cell carcinoma, at sitesE in late G1 and by cyclin A in the S phase of DNA
synthesis, and cdc2 (formerly CDK1) is bound by cyclin away from the tumor. The number of glomeruli from
each case was counted on light microscopy, and the num-B in mitosis [reviewed in 17, 18]. Cyclin-CDK complexes,
in turn, are negatively regulated by CDK inhibitors [19]. ber of injured glomeruli was recorded in focal glomerular
diseases (FSGS, HIVAN, and CG).The Cip/Kip family of CDK inhibitors, which include
the individual proteins called p21Cip1/WAF1 (p21) [20, 21],
Antibodies usedp27Kip1 (p27) [22, 23], and p57Kip2 (p57) [24], inhibits cyclin
D-CDK4 and cyclin E-CDK2 in G1 and cyclin A-CDK2 The following primary antibodies were used: (1)
p21Cip1/Waf1 (p21), a mouse monoclonal antibody (clonein S phase. Recent studies have shown that p21 also
limits cyclin B-cdc2 in mitosis [25]. The CDK inhibitors SX118; Pharmingen, San Diego, CA, USA) was raised
against a purified recombinant human p21-GST fusionp21, p27, and p57 are constitutively expressed in certain
cell types, and there is a growing body of evidence that protein [30]. This antibody reacts with amino acids 145
to 165 of human p21 and has been characterized byindividual members of the Cip/Kip family of CDK inhibi-
tors also have a critical role in the differentiation of immunostaining and Western blot analysis. (2) p27Kip1
(p27) is a goat polyclonal antibody (C-19; Santa Cruzcertain cell types [24, 26–29].
The purpose of the current study was to examine which Biotechnology, Santa Cruz, CA, USA) that maps to an
epitope to the carboxy terminus of p27 and has beencell cycle-regulatory proteins contribute to the mainte-
nance of a differentiated and quiescent podocyte pheno- characterized by Western blot analysis [31, 32]. In the
current study, staining was abolished by preabsorbingtype in certain forms of glomerular disease and which
contribute to processes of de-differentiation and prolif- the antibody with immunizing peptide (Santa Cruz Bio-
technology). (3) p57Kip2 (p57; C-20 Santa Cruz Biotech-eration in other forms of injury. We examined the expres-
sion of the Cip/Kip CDK inhibitors p21, p27, and p57 nology) is a rabbit polyclonal antibody raised against a
peptide corresponding to amino acids 286 to 305 of thein different human glomerular diseases in which podo-
cytes are the major target of injury. p27 and p57 are carboxy terminus of human p57. This antibody has been
previously characterized by immunoblotting and immu-constitutively expressed in mature podocytes, but p21 is
not (in agreement with previous studies by ourselves [27] nohistochemistry [28]. In the current study, immuno-
staining was abolished by preabsorbing the antibody withand others [28]). A decrease in these levels of p27 and
p57 and a corresponding de novo expression of p21 coin- the immunizing peptide (Santa Cruz Biotechnology). (4)
Ki-67, clone MIB-1, is a murine monoclonal antibodycide with podocyte proliferation and an immature phe-
notype. (Coulter/Immunotech, Miami, FL, USA) that reacts with
the proliferation-associated Ki-67 antigen and has been
previously shown to correlate with DNA synthesis after
METHODS
antigen retrieval.
Source of tissue
ImmunostainingCases of minimal change disease (MCD; N 5 6), cellu-
lar FSGS (N 5 12), collapsing glomerulopathy (CG; N 5 Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tissue sections following proto-9), and human immunodeficiency virus-associated ne-
phropathy (HIVAN; N 5 16) were selected retrospec- cols that we have previously reported [27]. Four-micron
thick sections of tissue samples were deparaffinized intively from the archives of the Renal Pathology Labora-
tory of Columbia University. All biopsies had been xylene and rehydrated in graded ethanols. Endogenous
peroxidase was blocked by incubation in 3% hydrogenperformed in the two-year period of 1998 to 1999. Cases
of membranous glomerulopathy (MGN; N 5 20) were peroxide. Sections were pretreated by steam heating for
20 minutes in Antigen Unmasking Solution (Vector Lab-selected retrospectively from the archives of the Univer-
sity of Washington Renal Pathology Laboratory. All pa- oratories, Burlingame, CA, USA) according to the man-
ufacturer’s instructions. Non-specific antibody bindingtients were biopsied for investigation of nephrotic pro-
teinuria, with or without associated renal insufficiency. was blocked by incubation for 30 minutes in 10% normal
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Table 1. Characteristics of biopsies studied
N total Average N % of glomeruli with
Disease N patients glomeruli glomeruli/case podocyte pathology/biopsya
MCD 6 67 11.17 0 (0.67)
MGN 19 247 26 0 (0/247)
Cellular FSGS 12 196 16.33 56.12 (110/196)
Collapsing GN 9 117 13.0 66.66 (78/117)
HIVAN 15 203 13.53 71.43 (145/203)
Uniform patterns in disease in which only a percentage of glomeruli demonstrated characteristic histopathologic changes. Histologically uninvolved glomeruli
followed the patterns of CDK-inhibitors and Ki-67 expression observed in cases of MCD and MGN. The patterns in glomeruli with collapsing and sometimes
sclerosing lesions with characteristic podocyte changes also demonstrated uniform patterns of altered CDK-inhibitor expression, as illustrated in Figures 4 and 5.
a Assessment by light microscopy
mouse serum (for monoclonal antibodies) or 10% nor- (Fig. 1E) and was also not detected in MCD (results
not shown) and membranous nephropathy (Fig. 3E).mal rabbit serum (for polyclonal antibodies). The tissue
In contrast, there was a marked increase in glomerularsections were then incubated for one hour at room tem-
immunostaining for Ki-67 in the cellular variant of FSGSperature (p27, p57, Ki-67) or overnight at 48C (p21)
(Fig. 4E), CG, and HIVAN (Fig. 5E). In glomeruli inwith the primary antibody diluted in phosphate-buffered
which the features of collapse or of cellular FSGS weresaline (PBS) plus 1% bovine serum albumin (BSA;
segmentally distributed, the expression of the Ki-67 anti-Sigma, St. Louis, MO, USA). After PBS washes, tissue
gen was also segmentally distributed and correspondedsections were incubated sequentially with a biotinylated
to the histologic alterations. Our results showed that Ki-67secondary antibody, the ABC-Elite Reagent (Vector
staining divided diseases of the podocyte into those inLaboratories) and with 3.39-diaminobenzidine with nickel
which the podocyte maintained a differentiated and qui-chloride enhancement. A methyl green nuclear counter
escent phenotype (MCD, membranous nephropathy)stain was used. Tissue from placenta and colon were
and those diseases associated with a de-differentiatedused as positive controls for the antibodies to p21 and
and proliferative phenotype (cellular variant of FSGS,p57 [33]. Human fetal kidney was used as a positive
CG, and HIVAN).control for p27 and p57, as previously described [27, 28].
Negative controls for immunostaining consisted of Differential expression of CDK inhibitors in normal
substituting the primary antibody with an irrelevant iso- human glomeruli
type-matched murine monoclonal antibody (Dako, Car-
Immunostaining for p57 was abundant and restrictedpinteria, CA, USA) or nonimmune rabbit serum (Dako).
to normal podocytes and was not present in glomerularJones’ silver methamine staining was performed on his-
mesangial and endothelial cells (Fig. 1B). The CDK in-
tologic sections from all cases using conventional proce-
hibitor p27 is constitutively expressed in normal human
dures.
glomeruli (Fig. 1C). Although positive nuclear staining
was rarely detected in all three resident glomerular cell
types in normal kidneys, immunostaining for p27 wasRESULTS
abundant in podocytes (Fig. 1C).Ki-67 immunostaining separates different types of
Immunostaining for p21 was not detected in normalglomerular diseases
glomeruli (Fig. 1D). Positive controls included concur-
Table 1 shows the total number of glomeruli examined rent p21 immunostaining in tubulointerstitial cells and
in each glomerular disease, the average number of glo- in the smooth muscle cells in small arteries in the same
meruli studied in individual cases, and the percentage tissue sections and demonstration of p21 expression in
of glomeruli with disease in the focal diseases. We stress simultaneously processed, and stained tissue sections
that the immunostaining patterns described later in this from placenta where p21 expression have been well de-
article were homogeneous for all glomeruli in the cases fined [30, 33].
of MCD and membranous glomerulonephritis and were
Expression of CDK inhibitors in nonproliferativehomogeneous in those glomeruli or segments of glomer-
glomerular diseases (MCD and MGN)uli exhibiting the characteristic pathology of cellular
FSGS, CG, and HIVAN, as illustrated in Figures 1–5. Podocyte expression of p27 and p57 was well pre-
To determine the presence of DNA synthesis and en- served in all glomeruli in MCD (Fig. 2) and MGN (Fig.
try into S phase of the cell cycle, tissue sections were 3). The glomerular expression of p21 was undetectable
stained with an antibody to the proliferation antigen Ki-67. in these diseases (Figs. 2 and 3). These results show that
the glomerular expression of the CDK inhibitors p21,Ki-67 immunostaining was absent in normal podocytes
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Fig. 1. Normal mature adult kidney. (A) Silver methamine-stained his-
tologic sections showing intact glomerulus, tubules, and interstitium.
(B) p57. p57 is widely expressed by podocyte nuclei and parietal epithe-
lial cell nuclei, as well as by some tubular epithelial cells. (C) p27. The
pattern of p27 expression in podocytes is indistinguishable from that
observed for p57. There are unidentified cell types in the glomerulus
that also express p27, with generally weaker staining that localize to
podocytes. (D) p21. In contrast, expression of p21 is largely absent in
the mature glomerulus. (E) Ki-67. Ki-67 staining is largely absent in
normal glomeruli and follows a similar pattern to p21.
p27, and p57 was indistinguishable from normal adult decrease in intensity of p57 staining in glomeruli in which
nephrectomy specimens that did not have glomerular proliferation was not pronounced (results not shown).
disease (Fig. 1). In areas of proliferation, there was a segmental absence
of podocyte immunostaining for p57. The absence was
Expression of CDK inhibitors in proliferative not due to cell loss, as nuclei were easily detected by the
glomerular diseases (cellular FSGS, CG, and HIVAN) methyl green counterstain. In many glomeruli in which
serial sections were available, there was a concordantChanges in p57 staining were also associated with po-
docyte proliferation (Figs. 4 and 5). There was a general decrease/absence of p27 and p57 immunostaining in
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Fig. 2. Serial sections of a representative glomerulus from a patient with minimal change disease (MCD). (A) Silver methamine-stained glomerulus
showing a histologically normal tuft architecture, tubules, and interstitium. (B) p57. The pattern of p57 expression is unchanged from the mature
normal glomerulus without disease. (C) p27. The pattern of p27 expression is unchanged from the normal mature glomerulus without disease. (D)
p21. There is an absence of p21 expression in this glomerulus that is unchanged from the normal mature glomerulus without disease.
identical segmental areas of proliferation in cellular staining. Nuclear immunostaining for p21 was detected in
FSGS, CG, and HIVAN (Figs. 4 and 5). podocytes and in mesangial and glomerular endothelial
In contrast to the nonproliferative glomerular dis- cells.
eases, there was a marked decrease in staining intensity
for p27 in the majority of glomeruli in patients with the
DISCUSSIONcellular variant of FSGS (Fig. 4C), CG, and HIVAN
The mature podocyte is a terminally differentiated cell(Fig. 5C), including glomeruli without histologically
that expresses specific differentiation markers, includingidentifiable lesions. Moreover, p27 immunostaining was
GLEPP-1, WT-1, C3b receptor, podocalyxin, and synap-not detected in segmental areas of podocyte prolifera-
topodin [reviewed in 34]. In contrast to immature podo-tion. Careful inspection of biopsies treated with nuclear
cytes, which proliferate during glomerular developmentcounterstained methyl green showed that the decrease
in utero, differentiated podocytes have a quiescent phe-or absence of p27 immunostaining was not due to the
notype [2]. The maintenance of a differentiated pheno-loss of podocyte number, but rather due to an absolute
type is required for podocytes to perform their special-decrease in nuclear staining.
ized functions [1]. The current study provides importantThere was a marked increase in p21 immunostaining in
evidence that human podocyte differentiation and prolif-the cellular variant of FSGS (Fig. 4D), CG, and HIVAN
eration in vivo may depend on the levels of specific CDK(diseases characterized by podocyte proliferation; Fig.
inhibitors. Our results show that the CDK inhibitors p275D). In these cases, the de novo staining for p21 was in
and p57, but not p21, are constitutively expressed ina segmental pattern, which spatially coincided with the
segmental decrease/absence of p27 and p57 immuno- normal differentiated podocytes, and persistent expres-
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Fig. 3. Serial sections of a representative glomerulus in a case of mem-
branous nephropathy. (A) Silver methamine-stained glomerulus show-
ing diffusely thickened capillary walls and epimembranous “spikes” of
matrix characteristic of this disease. (B) p57. The pattern of p57 expres-
sion by podocytes is similar to that identified in mature kidneys and in
MCD. (C) p27. The pattern of expression in p27 by podocytes is similar
to that seen in the mature kidney and in MCD. (D) p21. There is an
absence of p21 expression similar to that seen in the mature kidney
and MCD. (E) Ki-67. Glomeruli rarely exhibit staining of individual
cells indicative of cell proliferation, but these cannot be clearly identified
as podocytes based on their location within the glomerular tuft. Cells
identifiable as podocytes in case of membranous nephropathy never
exhibit staining for Ki-67.
sion of these molecules following injury is associated entially expressed in normal human podocytes. Both p27
and p57 are constitutively expressed in mature podo-with the persistence of a quiescent (nonproliferative)
phenotype. In contrast, glomerular diseases associated cytes, where the CDK inhibitor p21 is not detected.
These findings are consistent with previous studies bywith a decrease in podocyte expression of p27 and p57
lose the mature phenotype and acquire a proliferative our group and others showing that podocyte differentia-
tion and exit from the cell cycle during glomerulogenesisand immature phenotype.
In the current study, it was found that individual pro- coincides with the de novo expression of p27 and p57,
but not p21 [27, 28].teins of the Cip/Kip family of CDK inhibitors are differ-
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Fig. 4. Serial sections of a glomerulus demonstrating the cellular vari-
ant of focal segmental glomerulosclerosis (FSGS). Silver methamine-
stained glomerulus showing a segmental capillary collapse, capillary
obliteration, prominence of adjacent podocytes, and architectural pres-
ervation of other portions of the glomerular tuft. The area of segmental
involvement is outlined by arrows. (B) p57. The area of injury is high-
lighted by arrows and shows absence of p57 expression. A preserved
portion of the glomerular tuft shows persistence of p57 expression by
podocytes in a pattern similar to that illustrated in Figures 1B, 2B, and
3B. (C) p27. As in panel B, the segmental area of injury shows loss of
p27 expression, while the preserved portions of the glomerular tuft
demonstrate persistent p27 expression similar to that illustrated in Fig-
ures 1C, 2C, and 3C. (D) p21. In contrast, there is markedly up-regulated
expression of p21 in the diseased glomerular segment with characteristic
absent expression of this molecule in the preserved portion of these
glomeruli. (E) Ki-67. In conjunction with up-regulated expression of
p21 and down-regulated expression of p57 and p27 in the disease seg-
ment, there is localized cell proliferation indicated by staining for the
Ki-67 antigen.
Podocytes maintain a differentiated and nonprolifera- forms of glomerular disease, including HIVAN [11]. A
second major finding in this study was that the immuno-tive phenotype in MCD and membranous nephropathy.
In contrast, podocytes re-enter the cell cycle and acquire staining for the CDK inhibitors p27 and p57 did not
decrease in MCD. Furthermore, p27 was not altered ina proliferative phenotype in the cellular variant of FSGS
[10], idiopathic CG [11], and HIVAN [11] resembling membranous nephropathy, although there was a de-
crease in the intensity of p57 immunostaining in podo-an immature phenotype. Moreover, Barisoni et al have
shown that podocyte proliferation is associated with a cytes in some biopsies exhibiting membranous nephropa-
thy. In contrast, there were two patterns of p27 and p57loss of the differentiated markers such as WT-1 in certain
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Fig. 5. Serial sections of HIV-associated nephropathy (HIVAN)/col-
lapsing glomerulopathy (CG). The case illustrates a glomerulus from
a patient with HIVAN, of silver methamine-stained section showing
characteristic capillary collapse and prominence of podocytes. (B) p57.
p57 expression is absent in the prominent podocyte layer in this disease
process. (C) p27. Expression of p27 is absent in the prominent podocyte
layer in this disease. (D) p21. In contrast, there is markedly up-regulated
expression of p21 by glomerular cells, most often having a location
consistent with or characteristic of podocytes. (E) Ki-67. There is up-
regulated expression of Ki-67, usually in areas in which there is concomi-
tant areas of increased p21. Some, but not all, Ki-67 expression in cells
has a location indicative of podocyte phenotype. There is a tissue fold
(arrowhead) resulting in focal distortion of the glomerular appearance
in this serially sectioned glomerulus.
expression noted in cellular FSGS, CG, and HIVAN. not due to a loss of cell number because podocyte nuclei
were present and easily identified in the conventionallyFirst, there was a segmental absence of immunostaining
for both p27 and p57 in a distribution that was nearly stained histologic preparations. These findings support
a paradigm in which the reduction in p27 and p57 pre-identical to that of Ki-67 expression in areas of podocyte
DNA synthesis in individual glomeruli. Second, histolog- cedes the development of histologically identifiable glo-
merular lesions.ically “normal” glomeruli present in cases of cellular
FSGS, CG, and HIVAN demonstrated a general de- Experimental studies also have shown a role for p27
in podocyte proliferation. A lack of podocyte prolifera-crease in staining intensity for p27 and p57 in the podo-
cytes. The decrease in p27 and p57 immunostaining was tion in the passive Heymann nephritis model of experi-
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mental membranous nephropathy coincides with in- mesangial cell proliferation. The absence of podocyte
creased p27 levels in injured podocytes [35]. It has been proliferation in experimental membranous nephropathy
shown that p27 binds to and inhibits CDK2 activity in (passive Heymann nephritis model) also coincides with a
experimental membranous nephropathy, thereby lim- marked increase in p21 expression, and lowering p21 levels
iting podocyte proliferation [35]. Immune-mediated glo- with the mitogenic growth factor basic fibroblast growth
merulonephritis in p27 null mice is associated with in- factor in rats with passive Heymann nephritis are associ-
creased glomerular cell proliferation compared with ated with low-grade podocyte proliferation [35]. Finally,
controls, and the proliferating cells in nephritic p27 null we have recently shown that podocyte proliferation is
mice were typically podocytes [36]. Taken together, the markedly increased in experimental glomerulonephritis
current study shows that p27 levels may have a critical in mice made genetically deficient in p21 (p212/2) com-
role in podocyte differentiation and proliferation in hu- pared with nephritic p211/1 mice [40].
man glomerular disease. The persistence/maintenance of Second and mechanistically more confusing is that re-
p27 expression in MCD and membranous nephropathy cent studies have shown that small increases in p21 levels
was associated with and may be responsible for a differ- may serve to facilitate proliferation by providing a “scaf-
entiated and quiescent podocyte phenotype, whereas a fold-like” function for the assembly of cyclins, CDKs,
decrease in p27 levels in the cellular variant of FSGS, and proliferating cell nuclear antigen [41]. Thus, one may
collapsing GN, and HIVAN is closely correlated with speculate that the increase in p21 in certain podocyte
podocyte proliferation and may be necessary for these diseases facilitates proliferation in the absence of other
processes to develop. CDK inhibitors such as p27 and p57. Third, Nagata et
The CDK inhibitor p57 also regulates cell proliferation al has shown that p21 is transiently increased during
and differentiation [37]. p57 is typically expressed in
podocyte development so that the increased expression
differentiated and postmitotic nonrenal cells [24], and
could be a manifestation of an immature phenotype, inde-we (unpublished data) and others have shown that there
pendent of its regulatory role for cell proliferation [28].is de novo expression of p57 in podocytes during glomer-
In summary, the results of the current study show aulogenesis that coincides with p27 expression and with
role for specific cell cycle proteins in glomerular diseasepodocyte acquisition of a terminally differentiated phe-
characterized by podocyte injury. In diseases character-notype. In the current study, we show that a decrease
ized by podocyte proliferation, the decreased expressionor absence of p57 immunostaining was associated with
of specific CDK inhibitors is similar to their pattern ofan immature and proliferative podocyte phenotype in
expression during early podocyte development. The cor-human disease. However, a decrease in p57 immuno-
ollary of this is also true in that we show that the presencestaining alone, suggestive of diminished but not absent
of the CDK inhibitors p27 and p57 is associated with thelevels of p57 peptide, was apparent in membranous ne-
persistence of a differentiated and quiescent podocytephropathy without a concomitant decrease in p27 levels.
phenotype, and is consistent with the general notion thatThis constellation of findings was not sufficient for de-
the principal function of these molecules is to inhibit cellmonstrable proliferation. Taken together, our results in-
proliferation. Recent evidence that p21, often considereddicate that the inhibitory threshold imposed by both p27
and p57 needs to be overcome in order for podocytes to function as a suppressor of cell proliferation like p27
to proliferate and acquire an immature phenotype. and p57, has more complex biologic functions that include
A third and surprising major finding in the current facilitation of cell proliferation, is further supported by
study was that the pattern of expression for the CDK our demonstration that p21 expression in podocytes is
inhibitor p21 was different from p27 and p57. Immuno- associated with a pro-proliferative antiquiescent effect.
staining for p21 was absent in normal glomeruli and did The potential diagnostic implications of this study is that
not increase in MCD and membranous nephropathy. In determining the expression of specific cell cycle proteins
contrast to p27 and p57, p21 expression increased during may assist in differentiating the different forms of podo-
podocyte proliferation in the cellular variant of FSGS, cyte diseases.
collapsing GN, and HIVAN. We can only speculate on
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